DE10323758A1 - Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen - Google Patents
Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen Download PDFInfo
- Publication number
- DE10323758A1 DE10323758A1 DE10323758A DE10323758A DE10323758A1 DE 10323758 A1 DE10323758 A1 DE 10323758A1 DE 10323758 A DE10323758 A DE 10323758A DE 10323758 A DE10323758 A DE 10323758A DE 10323758 A1 DE10323758 A1 DE 10323758A1
- Authority
- DE
- Germany
- Prior art keywords
- surfactants
- polydimethylsiloxane
- weight
- proportion
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 13
- 201000011510 cancer Diseases 0.000 title claims abstract description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 18
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 18
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims description 10
- 229940126601 medicinal product Drugs 0.000 claims description 9
- 229910021536 Zeolite Inorganic materials 0.000 claims description 7
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 7
- 239000010457 zeolite Substances 0.000 claims description 7
- 239000003945 anionic surfactant Substances 0.000 claims description 6
- 239000010459 dolomite Substances 0.000 claims description 6
- 229910000514 dolomite Inorganic materials 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002280 amphoteric surfactant Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000011034 rock crystal Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10323758A DE10323758A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
| AU2004243524A AU2004243524A1 (en) | 2003-05-22 | 2004-05-19 | Medicament for internal application, in particular against cancerous diseases |
| RU2005140097/15A RU2005140097A (ru) | 2003-05-22 | 2004-05-19 | Лекарственное средство для внутреннего применения, в частности, против раковых заболеваний |
| JP2006529603A JP2006528211A (ja) | 2003-05-22 | 2004-05-19 | 癌治療用の内服用の薬 |
| US10/557,317 US20070172435A1 (en) | 2003-05-22 | 2004-05-19 | Medicament for internal application, in particular against cancerous diseases |
| PCT/DE2004/001048 WO2004105776A1 (de) | 2003-05-22 | 2004-05-19 | Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen |
| EP04733761A EP1635849A1 (de) | 2003-05-22 | 2004-05-19 | Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen |
| CA002526175A CA2526175A1 (en) | 2003-05-22 | 2004-05-19 | Medicament for internal application, in particular against cancerous diseases |
| CNA2004800140406A CN1795001A (zh) | 2003-05-22 | 2004-05-19 | 内用药物,更具体为用于治疗癌症的内用药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10323758A DE10323758A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10323758A1 true DE10323758A1 (de) | 2004-12-16 |
Family
ID=33441299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10323758A Withdrawn DE10323758A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070172435A1 (https=) |
| EP (1) | EP1635849A1 (https=) |
| JP (1) | JP2006528211A (https=) |
| CN (1) | CN1795001A (https=) |
| AU (1) | AU2004243524A1 (https=) |
| CA (1) | CA2526175A1 (https=) |
| DE (1) | DE10323758A1 (https=) |
| RU (1) | RU2005140097A (https=) |
| WO (1) | WO2004105776A1 (https=) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007043759A1 (de) | 2007-09-13 | 2008-09-11 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102007043748A1 (de) | 2007-09-13 | 2008-09-11 | Basf Se | Verfahren zur kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102007043758A1 (de) | 2007-09-13 | 2008-10-23 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat des Zielproduktes X |
| DE102008042008A1 (de) | 2007-09-13 | 2009-04-09 | Basf Se | Verfahren zur kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102009045767A1 (de) | 2009-10-16 | 2010-08-12 | Basf Se | Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge |
| DE102010030279A1 (de) | 2010-06-18 | 2010-10-28 | Basf Se | Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge |
| WO2011045356A1 (de) | 2009-10-16 | 2011-04-21 | Basf Se | Verfahren der inbetriebnahme eines trennverfahrens zur reinigenden abtrennung von acrylsäurekristallen aus einer suspension s ihrer kristalle in mutterlauge |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10323759A1 (de) * | 2003-05-22 | 2004-12-16 | Bauer, Wulf, Dr. | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
| EP3223828B1 (en) * | 2014-11-24 | 2020-06-17 | University Of Technology, Sydney | Methods for the treatment and prevention of asbestos-related diseases |
| CN104606261B (zh) * | 2015-03-05 | 2018-02-09 | 潘友长 | 一种沸石药物组合物及其制备方法和用途 |
| CN105837734A (zh) * | 2016-05-09 | 2016-08-10 | 上海惠昌化工厂 | 有机硅改性丙烯酸聚酯钾盐及制备方法和防癌治癌用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310572A (en) * | 1987-02-03 | 1994-05-10 | Dow Corning Corporation | Process for forming a coated active agent-containing article |
| US5418220A (en) * | 1994-03-08 | 1995-05-23 | Schmidt; Alfred | Method for treating constipation using dimethicone |
| US5587149A (en) * | 1995-02-06 | 1996-12-24 | R.P. Scherer Corporation | Topical application emulsions |
| DE19780248D2 (de) * | 1996-03-25 | 1999-03-11 | Bauer Wulf Dr | Heilmittel zur äußerlichen Anwendung und Verwendung einer wässrigen Öl-Emulsion für ein derartiges Heilmittel |
| US6347408B1 (en) * | 1998-11-05 | 2002-02-19 | Allegiance Corporation | Powder-free gloves having a coating containing cross-linked polyurethane and silicone and method of making the same |
| EP1316530B1 (de) * | 1999-04-26 | 2004-12-15 | Tihomir Lelas | Mikronisierte Zoelithe zur Verwendung als pharmazeutisches Mittel |
-
2003
- 2003-05-22 DE DE10323758A patent/DE10323758A1/de not_active Withdrawn
-
2004
- 2004-05-19 WO PCT/DE2004/001048 patent/WO2004105776A1/de not_active Ceased
- 2004-05-19 JP JP2006529603A patent/JP2006528211A/ja not_active Withdrawn
- 2004-05-19 RU RU2005140097/15A patent/RU2005140097A/ru unknown
- 2004-05-19 EP EP04733761A patent/EP1635849A1/de not_active Withdrawn
- 2004-05-19 CN CNA2004800140406A patent/CN1795001A/zh active Pending
- 2004-05-19 AU AU2004243524A patent/AU2004243524A1/en not_active Abandoned
- 2004-05-19 CA CA002526175A patent/CA2526175A1/en not_active Abandoned
- 2004-05-19 US US10/557,317 patent/US20070172435A1/en not_active Abandoned
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007043759A1 (de) | 2007-09-13 | 2008-09-11 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102007043748A1 (de) | 2007-09-13 | 2008-09-11 | Basf Se | Verfahren zur kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102007043758A1 (de) | 2007-09-13 | 2008-10-23 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat des Zielproduktes X |
| DE102008042009A1 (de) | 2007-09-13 | 2009-04-09 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat des Zielproduktes X |
| DE102008042008A1 (de) | 2007-09-13 | 2009-04-09 | Basf Se | Verfahren zur kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102008042010A1 (de) | 2007-09-13 | 2009-04-16 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| DE102009045767A1 (de) | 2009-10-16 | 2010-08-12 | Basf Se | Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge |
| WO2011045356A1 (de) | 2009-10-16 | 2011-04-21 | Basf Se | Verfahren der inbetriebnahme eines trennverfahrens zur reinigenden abtrennung von acrylsäurekristallen aus einer suspension s ihrer kristalle in mutterlauge |
| US8461383B2 (en) | 2009-10-16 | 2013-06-11 | Basf Se | Process for starting up a separating process for purifying removal of acrylic acid crystals from a suspension S of crystals thereof in mother liquor |
| DE102010030279A1 (de) | 2010-06-18 | 2010-10-28 | Basf Se | Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005140097A (ru) | 2006-08-10 |
| CN1795001A (zh) | 2006-06-28 |
| JP2006528211A (ja) | 2006-12-14 |
| CA2526175A1 (en) | 2004-12-09 |
| WO2004105776A1 (de) | 2004-12-09 |
| EP1635849A1 (de) | 2006-03-22 |
| AU2004243524A1 (en) | 2004-12-09 |
| US20070172435A1 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10323758A1 (de) | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen | |
| DE10323759A1 (de) | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen | |
| DE19749724A1 (de) | Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln | |
| DE2113215A1 (de) | Therapeutisches Kompositum | |
| DE2504331A1 (de) | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung | |
| DE69100954T2 (de) | Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung. | |
| DE1767017A1 (de) | Eisenpraeparat | |
| JP2006528211A5 (https=) | ||
| JP2006528210A5 (https=) | ||
| AU2011304259A8 (en) | Antimicrobial and wound-healing action pharmaceutical composition for external application process of producing the same | |
| WO2014045083A1 (en) | Process for bio synthesis of nano arsenic trioxide and its use in treatment of diseases including cancers | |
| EP0256353A2 (de) | Pharmazeutikum zur Therapie einer schlechten Absorption von Nahrungsmitteln und von Oral einzunehmenden Medikamenten | |
| DE102015002709A1 (de) | Neue Verwendung von Acetylsalicylsäure und einem Derivat davon | |
| DE10142996A1 (de) | Verwendung von Wirkstoffen mit mu-Opioid-Rezeptor agonistischer Wirkung als Kombinationsarzneimittel zur Krebsbehandlung | |
| DE102005020467A1 (de) | Mittel zur Therapie und Prophylaxe von Hauterkrankungen | |
| JPH06316515A (ja) | 浴用剤組成物 | |
| EP3373911A1 (de) | Kombination von calciumsulfat und gummi arabicum | |
| EP2509613A1 (de) | Zusammensetzung zur behandlung von magen- und darmbeschwerden | |
| CN106806411A (zh) | 治疗或缓解呼吸系统疾病症状的外用药物及其制备方法 | |
| US244965A (en) | Medical compound | |
| DE102023124464A1 (de) | Kosmetische oder dermatologische Zubereitung und Verfahren zur Herstellung einer solchen Zubereitung | |
| DE102011114455A1 (de) | Nahrungsergänzungsmittel oder dergleichen | |
| DE3835864C2 (https=) | ||
| DE10246206A1 (de) | Topische Zusammensetzung enthaltend Rauchagglomerate | |
| DE10116175A1 (de) | Verwendung von löslichem Stoffinventar aus Wurzeln von Salvia officinalis zur Behandlung von ulcerösen Zuständen im Magen-Darmtrakt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |